NDC 65044-0546-02: Standardized Grass Pollen, Bluegrass, Kentucky June 100000 [BAU]/mL Injection, Solution, 10 mL Vial
This is a package of 10 mL of Standardized Grass Pollen, Bluegrass, Kentucky June 100000 [BAU]/mL Injection, Solution from Jubilant HollisterStier LLC, no longer marketed (first marketed Jan 1998), no longer in the FDA NDC Directory.
NDC database record
One package, one record: these facts belong to NDC 65044-0546-2 alone.
- Record
- FDA NDC Directory package listing · Standardized allergenic
- Code segments
- 65044 labeler · 0546 product · 2 package
- Package marketed since
- Jan 15, 1998
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 6504405462 5
- FDA record last changed
- Oct 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 65044-0546-01 65044-0546-1 Main listing | 5 mL in 1 VIAL | 1998-01-15 | — | Discontinued by firm |
| 65044-0546-02 You're viewing this | 10 mL in 1 VIAL | 1998-01-15 | — | Discontinued by firm |
| 65044-0546-03 65044-0546-3 | 30 mL in 1 VIAL | 1998-01-15 | — | Discontinued by firm |
| 65044-0546-04 65044-0546-4 | 50 mL in 1 VIAL | 1998-01-15 | — | Discontinued by firm |
You're viewing one of 4 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 65044-0546-01?
What NDC number is used to bill for this package of Standardized Grass Pollen, Bluegrass, Kentucky June 100000 [BAU]/mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Kentucky Bluegrass (June) Standardized 100000 [BAU]/mL 00268-0283-10 | ALK-Abello, | 10 ml | — | — | FDA listed | — |
| Kentucky Bluegrass (June) Standardized 100000 [BAU]/mL 00268-3051-06 | ALK-Abello, | 5 ml | — | — | FDA listed | — |
| Standardized Kentucky (June) Bluegrass Pollen 100000 [BAU]/mL 22840-0202-02 | Greer | 10 ml | — | — | FDA listed | — |
| Standardized Kentucky Blue (June) Grass 100000 [BAU]/mL 49643-0393-05 | Allermed | 5 ml | — | — | FDA listed | — |
| Standardized Grass Pollen, Bluegrass, Kentucky June 100000 [BAU]/mLthis 65044-0546-02 | Jubilant | 10 ml | — | — | Discontinued | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Mar 13, 2036 |
Is there a biosimilar for this drug?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Jubilant HollisterStier LLC labeler code 65044
- bicisate dihydrochloride .9 mg Injection NDC 65044-0010-1
- tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate 1 mg/mL Injection, Powder, Lyophilized, For Solution NDC 65044-0020-1
- perflutren 6.52 mg/mL Injection, Suspension NDC 65044-0040-1
- Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution NDC 65044-0537-1
- Standardized Grass Pollen, Bluegrass, Kentucky June 10000 [BAU]/mL Injection, Solution NDC 65044-0545-1
- Standardized Grass Pollen, Fescue, Meadow 10000 [BAU]/mL Injection, Solution NDC 65044-0611-1
- Standardized Grass Pollen, Fescue, Meadow 100000 [BAU]/mL Injection, Solution NDC 65044-0612-1
- Standardized Grass Pollen, Orchard 10000 [BAU]/mL Injection, Solution NDC 65044-0718-1
- Standardized Grass Pollen, Orchard 100000 [BAU]/mL Injection, Solution NDC 65044-0719-1
- Standardized Grass Pollen, Redtop 10000 [BAU]/mL Injection, Solution NDC 65044-0777-1
- Standardized Grass Pollen, Redtop 100000 [BAU]/mL Injection, Solution NDC 65044-0778-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
WARNING: ANAPHYLAXIS Standardized Grass Pollen Extracts can cause anaphylaxis, including anaphylactic shock and death 1 . ( 5.1 , 11 ) Do not administer to individuals with: severe, unstable or uncontrolled asthma; history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment; medical conditions that reduce the ability to survive anaphylaxis. ( 4 ) Observe individuals for at least 30 minutes following administration.
Emergency measures and healthcare providers trained in their use must be available in the event of a life‑threatening reaction. ( 5.1 ) Individuals with extreme sensitivity to these products, on an accelerated immunotherapy build-up, switching to another lot, receiving high doses of these products, or exposed to excessive amounts of grass pollen may be at increased risk of anaphylaxis. ( 5.1 ) These products may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
( 5.1 ) WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning . Standardized Grass Pollen Extracts can cause anaphylaxis, including anaphylactic shock and death. ( 5.1 ) Do not administer to individuals with severe, unstable or uncontrolled asthma, history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment, or with medical conditions that reduce the ability to survive anaphylaxis.
( 4 ) Observe individuals for at least 30 minutes following administration. Emergency measures and healthcare providers trained in their use must be available in the event of a life-threatening reaction. ( 5.1 ) Individuals with extreme sensitivity to these products, on an accelerated immunotherapy build-up, switching to another lot, receiving high doses of these products, or exposed to excessive amounts of grass pollen may be at increased risk of anaphylaxis.
( 5.1 ) These products may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. ( 5.1 )
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Standardized Grass Pollen Extracts [see Description ( 11 )] are indicated for: Skin testing for diagnosis of patients with a clinical history of allergy to one or more of the following grass pollen allergens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy. 7 , 8 , 9 , 10 Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies for Bermuda grass pollen, Kentucky Blue (June) grass pollen, Meadow Fescue grass pollen, Orchard grass pollen, Perennial Rye grass pollen, Redtop grass pollen, Sweet Vernal grass pollen, or Timothy grass pollen.
Standardized Grass Pollen Extracts are indicated for ( 1 ): Skin test diagnosis of patients with a clinical history of allergy to one or more of the following grass pollen allergens: Bermuda,Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy. Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies to one or more of the following grass pollens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy.
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For percutaneous, intradermal, or subcutaneous use only . Administration: Percutaneous for diagnostic testing Intradermal for diagnostic testing Subcutaneous for immunotherapy See full prescribing information for details on dosing and dilution preparation. ( 2 )
2.1Preparation for Administration Verify that the label on the vial states the intended specific standardized grass pollen extract to be administered. Standardized Grass Pollen Extracts should appear as clear to slightly opalescent solution with a light yellow to medium brown color. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Discard the solution if either of these conditions exist. Standardized Grass Pollen Extracts diluted with Albumin Saline with Phenol (0.4 %) (stabilized diluent) may be more potent than Standardized Grass Pollen Extracts diluted with diluents that do not contain albumin. When switching from non‑stabilized to stabilized diluent, consider less concentrated initial dilutions for both intradermal testing and immunotherapy.
Different formulations, preparations, or new lots of Standardized Grass Pollen Extracts are not substitutable. Adjust dosage appropriately when formulations, preparations, or lots of Standardized Grass Pollen Extracts are changed [see Immunotherapy ( 2.3 ) and Dosage Forms and Strengths ( 3 )] . Standardized Grass Pollen Extracts may be prepared for intradermal (diagnosis) or subcutaneous (immunotherapy) administration by diluting stock concentrates.
For diluent, use sterile albumin saline with phenol or sterile normal saline with phenol. Dilute stock concentrates by a minimum of 100-fold for intradermal testing. Dilutions of 1,000-fold or greater are appropriate starting points for patients with a clinical history of adverse reaction.
To prepare dilutions for intradermal testing and immunotherapy, start with a stock concentrate, and prepare a ten-fold (1:10) dilution by adding 0.5 mL of concentrate to 4.5 mL of sterile aqueous diluent. Prepare subsequent dilutions in a similar manner (see Table 1). Table 1: 10-fold Dilution Series for Standardized Grass Pollen Extracts Labeled 10,000 BAU/mL* and 100,000 BAU/mL* Dilution** Extract Volume of Diluent Dilution Strength BAU/mL (Bermuda Grass) Dilution Strength BAU/mL (All other Individual Grasses, except Bermuda Grass) 0 Stock Concentrate 0 mL 10,000 100,000 1 0.5 mL Concentrate 4.5 mL 1,000 10,000 2 0.5 mL Dilution 1 4.5 mL 100 1,000 3 0.5 mL Dilution 2 4.5 mL 10 100 4 0.5 mL Dilution 3 4.5 mL 1 10 5 0.5 mL Dilution 4 4.5 mL 0.1 1 6 0.5 mL Dilution 5 4.5 mL 0.01 0.1 7 0.5 mL Dilution 6 4.5 mL 0.001 0.01 * BAU/mL = Bioequivalent Allergy Units/mL ** Store extract dilutions at 2 to 8 °C (36 to 46 °F).
2.2Diagnostic Testing For percutaneous and intradermal use only. Use individual standardized grass pollen extracts to identify patients who exhibit an allergic response to specific species of grass pollen. False positive reactions may occur.
A positive skin test reaction must be interpreted in the context of the individual’s clinical history and known exposure to the allergen. Administer percutaneous tests prior to administration of intradermal tests. A positive reaction with grass pollen mixtures during diagnostic testing does not permit identification of the specific grass pollen allergen that elicited the reaction.
Additionally, a negative reaction fails to indicate whether an individual component allergen would have elicited a positive reaction at full strength. Percutaneous Skin Testing Dose Unless an individual is suspected to be at greater risk for anaphylaxis, the initial starting dose is 1 drop (approximately 0.05 mL) of concentrated standardized grass pollen extract. For individuals suspected to be at greater risk for anaphylaxis such as those with a history of allergen-induced anaphylaxis, initiate percutaneous testing with 1 drop of a d… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection. Standardized Grass Pollen Extracts are labeled in Bioequivalent Allergy Units per milliliter (BAU/mL). [see Description ( 11 )] Refer to the vial label for the product concentration [see How Supplied/Storage and Handling ( 16.1 )]. For percutaneous testing, standardized Bermuda grass pollen extract stock concentrate containing 10,000 BAU/mL of grass pollen is supplied in 10 mL multiple-dose vials.
All other standardized grass pollen extract stock concentrates containing 100,000 BAU/mL of grass pollen are supplied in 5 mL dropper vials [see Description ( 11 ) ]. For intradermal testing, standardized Bermuda grass pollen extract stock concentrate is available in 10,000 BAU/mL of grass pollen. All other standardized grass pollen extract stock concentrates are available in 100,000 BAU/mL.
All standardized grass pollen extract stock concentrates are supplied in 10 mL and 50 mL multiple-dose vials [see Description ( 11 ) ]. For immunotherapy, standardized Bermuda grass pollen extract stock concentrate is available in 10,000 BAU/mL. All other standardized grass pollen extract stock concentrates are available in 100,000 BAU/mL.
All standardized grass pollen extract stock concentrates are supplied in 10 mL and 50 mL multiple-dose vials [see Description ( 11 ) ]. Injection. Standardized Grass Pollen Extracts are labeled in Bioequivalent Allergy Units per milliliter (BAU/mL).
( 3 , 11 ) Refer to the vial label for the product concentration. ( 16 ) Standardized Bermuda grass pollen extract: 10,000 BAU/mL stock concentrate in a multiple-dose vial. ( 3 ) All other Standardized Grass Pollen Extracts (except Bermuda grass pollen): 100,000 BAU/mL stock concentrate in a multiple-dose dropper vial and in a multiple-dose vial.
( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Standardized Grass Pollen Extracts are contraindicated in individuals with: Severe, unstable or uncontrolled asthma. History of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. Medical conditions that reduce the ability to survive anaphylaxis.
Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment.( 4 ) Medical conditions that reduce the ability to survive anaphylaxis. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS The risk of anaphylaxis may be increased in the following situations ( 5.1 ): Extreme sensitivity to Standardized Grass Pollen Extracts. Receipt of an accelerated build-up schedule. Change from one lot of a particular standardized grass pollen extract to another lot of the same standardized grass pollen extract. Receipt of high doses of the Standardized Grass Pollen Extracts. Exposure to excessive amounts of grass pollen.
5.1Anaphylaxis Anaphylaxis, which may lead to death, can occur in individuals following the administration of Standardized Grass Pollen Extracts, particularly in the following situations [see Adverse Reactions ( 6 )]: 18 , 19 , 20 , 21 Extreme sensitivity to the Standardized Grass Pollen Extracts. Receipt of an accelerated build-up schedule. Change from one lot of a particular standardized grass pollen extract to another lot of the same standardized grass pollen extract.
Receipt of high doses of the Standardized Grass Pollen Extracts. Exposure to excessive amounts of grass pollen. Standardized Grass Pollen Extracts may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta‑blockers.
Medications to treat systemic reactions, as well as emergency equipment should be available for immediate use. Administer Standardized Grass Pollen Extracts in a healthcare setting under the supervision of a healthcare provider prepared to manage anaphylaxis. Individuals should remain in the provider’s office for a minimum of 30 minutes after receiving an injection of Standardized Grass Pollen Extracts, so that any adverse reaction can be observed and appropriately managed.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS Common adverse reactions reported for allergenic extracts are: Local adverse reactions occurred in 26 to 82 % of all patients who received subcutaneous immunotherapy, at the injection site (e.g., erythema, swelling, pruritus, tenderness and pain). 23 Systemic adverse reactions occurred in ≤ 7 % of patients who received subcutaneous immunotherapy (e.g., generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, hypotension, and shock). 24 Systemic reactions may be fatal.
1 , 12 , 23 Published studies of allergenic extracts report systemic reactions occurring in fewer than 1% in patients receiving conventional immunotherapy and greater than 36% in patients receiving rush immunotherapy. 1 , 12 , 26 , 27 Most systemic reactions occurred within 30 minutes of injection. However, systemic reactions have been reported to occur up to 2 hours after the final injection with rush schedules.
Some reactions have occurred up to 6 hours after skin tests or immunotherapy. 23 , 24 , 28 Commonly reported adverse reactions for allergenic extracts are: Local adverse reactions occurred in 26 to 82 % of all patients who received subcutaneous immunotherapy (e.g., erythema, swelling, pruritus, tenderness and pain at the injection site). ( 6 ) Systemic adverse reactions occurred in ≤ 7 % of patients who received subcutaneous immunotherapy (e.g., generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, hypotension, and shock).
Systemic adverse reactions may be fatal. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Jubilant HollisterStier at 1-800-495-7437 or [email protected]; or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Certain medications may decrease skin test wheal and erythema responses including antihistamine ( 7.1 ), topical corticosteroids and topical anesthetics ( 7.2 ), tricyclic Antidepressants ( 7.3 ).
7.1Antihistamines Do not perform skin testing with Standardized Grass Pollen Extracts within 3 to 10 days of first-generation H1‑histamine receptor blockers (e.g., clemastine, diphenhydramine) and second-generation antihistamines (e.g., loratadine, fexofenadine) being used. These products suppress histamine skin test reactions and could mask a positive response. 13 , 22 , 23
7.2Topical Corticosteroids and Topical Anesthetics Topical corticosteroids may suppress skin reactivity; therefore, discontinue use at the skin test site for at least 2 to 3 weeks before skin testing. 13 , 14 Avoid use of topical local anesthetics at skin test sites because they can suppress flare responses. 16 , 22 , 23
7.3Tricyclic Antidepressants Tricyclic antidepressants, such as doxepin, can have potent antihistamine effects and may alter skin test results. Allow 7 to 14 days after discontinuation of tricyclic medication prior to skin testing. 15 , 22 , 23
👥 Use in Specific Populations ▾
8 USES IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20 %, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Extracts associated risks during pregnancy. 17
8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.
8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patient’s ability to comply and cooperate with receipt of the product and the potential for difficulty in communicating with the child regarding systemic reactions. 11 , 23 The volume of a dose for immunotherapy may need to be divided for pediatric patients [see Immunotherapy ( 2.3 )].
8.5Geriatric Use Data are not available to determine if patients 65 years of age and older respond differently to allergen immunotherapy than younger patients. 3
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20 %, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Extracts associated risks during pregnancy. 17
🧒 Pediatric Use ▾
8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patient’s ability to comply and cooperate with receipt of the product and the potential for difficulty in communicating with the child regarding systemic reactions. 11 , 23 The volume of a dose for immunotherapy may need to be divided for pediatric patients [see Immunotherapy ( 2.3 )].
🧓 Geriatric Use ▾
8.5Geriatric Use Data are not available to determine if patients 65 years of age and older respond differently to allergen immunotherapy than younger patients. 3
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The mechanisms of action of allergen immunotherapy have not been fully established.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The mechanisms of action of allergen immunotherapy have not been fully established.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied Standardized Grass Pollen Extracts are supplied as 50 % glycerin stock concentrates labeled in Bioequivalent Allergenic Units per Milliliter (BAU/mL) and provided in 10 mL and 50 mL multiple-dose vials for percutaneous and intradermal skin testing and subcutaneous immunotherapy. These extracts may also be supplied in 5 mL multiple-dose dropper vials for percutaneous testing only. These products are supplied as listed in Table 2.
Table 2: Available Standardized Grass Pollen Extracts Extracts Strength NDC Vial Size Standardized Grass Pollen, Bermuda Grass (Cynodon dactylon) 10,000 BAU/mL 65044-0537-2 10 mL 65044-0537-4 50 mL Standardized Grass Pollen, Kentucky Blue (June) (Poa pratensis) 100,000 BAU/mL 65044-0546-1 5 mL 65044-0546-2 10 mL 65044-0546-4 50 mL Standardized Grass Pollen, Fescue, Meadow ( Festuca elatior ) 100,000 BAU/mL 65044-0612-1 5 mL 65044-0612-2 10 mL 65044-0612-4 50 mL Standardized Grass Pollen, Orchard Grass (Dactylis glomerata) 100,000 BAU/mL 65044-0719-1 5 mL 65044-0719-2 10 mL 65044-0719-4 50 mL Standardized Grass Pollen, Redtop (Agrostis alba) 100,000 BAU/mL 65044-0778-1 5 mL 65044-0778-2 10 mL 65044-0778-4 50 mL Standardized Grass Pollen, Perennial Ryegrass (Lolium perenne) 100,000 BAU/mL 65044-0788-1 5 mL 65044-0788-2 10 mL 65044-0788-4 50 mL Standardized Grass Pollen, Sweet Vernal Grass (Anthoxanthum odoratum) 100,000 BAU/mL 65044-0826-1 5 mL 65044-0826-2 10 mL 65044-0826-4 50 mL Standardized Grass Pollen, Timothy (Phleum pratense) 100,000 BAU/mL 65044-0832-1 5 mL 65044-0832-2 10 mL 65044-0832-4 50 mL Standardized Grass Mix #4 (25% each of Poa pratensis , Dactylis glomerata , Agrostis alba , Phleum pratense ) 100,000 BAU/mL 65044-0842-1 5 mL 65044-0842-2 10 mL 65044-0842-4 50 mL
16.2Storage and Handling Store extracts at 2 to 8 °C (36 to 46 °F). Dilutions with under 50% glycerin are less stable. If potency loss is suspected, verify the potency by skin testing with equal units of a freshly prepared dilution on individuals with known pollen allergies.
📋 Description ▾
11 DESCRIPTION This prescribing information covers eight Standardized Grass Pollen Extracts. The term 'Standardized Grass Pollen Extracts' as used throughout labeling specifically refers to all eight products listed in the Product Title in Highlights of Prescribing Information. Standardized Grass Pollen Extracts include Standardized Bermuda Grass Pollen (Cynodon dactylon) at 10,000 BAU/mL, 0.5 % sodium chloride, 0.275 % sodium bicarbonate and 50 % glycerin by volume as a preservative and Standardized Kentucky Blue (June) Grass Pollen (Poa pratensis) , Standardized Meadow Fescue Grass Pollen (Festuca elatior) , Standardized Orchard Grass Pollen (Dactylis glomerata) , Standardized Perennial Rye Grass Pollen (Lolium perenne) , Standardized Redtop Grass Pollen (Agrostis alba) , Standardized Sweet Vernal Grass Pollen (Anthoxanthum odoratum) , and Standardized Timothy Grass Pollen (Phleum pratense) at 100,000 BAU/mL, 0.5 % sodium chloride, 0.275 % sodium bicarbonate, and 50 % glycerin by volume as a preservative.
Inactive ingredients include 0.25% sodium chloride for isotonicity and 0.25% sodium bicarbonate as a buffer. Standardized Grass Pollen Extracts are administered percutaneously, intradermally and subcutaneously. Standardized Grass Pollen Extracts are clear light yellow to brownish solutions that are free of particulate matter.
Standardized Grass Pollen Extracts are labeled in BAU/milliliter. Bioequivalent Allergy Units are assigned based on comparison by enzyme-linked immunosorbent assay (ELISA) to references from the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER).
CBER references are assigned unitage based on quantitative skin testing. 2 , 4 , 5 , 6 CBER references which can be diluted 1:5,000,000 to intradermally elicit a 50 millimeter sum of erythema diameter response in highly puncture reactive subjects are assigned 100,000 BAU/milliliter; whereas references diluted 1:500,000 which elicit the same 50 millimeter sum of erythema diameter response are assigned 10,000 BAU/milliliter.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Instruct patients to remain in the office under observation for a minimum of 30 minutes after an injection or longer, if deemed necessary for the individual. Inform patients that reactions may occur more than 30 minutes after skin testing or an injection. Instruct patients to recognize the following symptoms as systemic adverse reactions and seek emergency medical care right away if any of these occur: Unusual swelling and/or tenderness at the injection site Hives or itching of the skin Swelling of face and/or mouth Sneezing, coughing, or wheezing Shortness of breath Nausea Dizziness or faintness Manufacturer: Jubilant HollisterStier LLC Spokane, WA 99207 U.S.A.
U.S. Lic. No.
1272 385407-H09 Company Logo
🍼 Nursing Mothers ▾
8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Specific immunotherapy with allergenic extracts is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S. Food and Drug Administration, has been published. 25
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies in animals have been performed to evaluate carcinogenicity, mutagenicity or impairment of fertility.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies in animals have been performed to evaluate carcinogenicity, mutagenicity or impairment of fertility.
📚 References ▾
15 REFERENCES Lockey, Richard F., Linda M. Benedict, Paul C. Turkeltaub, Samuel C.
Bukantz. Fatalities from immunotherapy (IT) and skin testing (ST). J.
Allergy Clin. Immunol., 79 (4): 660-677, 1987. U.S.
Food & Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). ELISA competition assay (Enzyme-linked Immunosorbent Assay). Methods of Allergenic Products Testing Laboratory.
October 1993. CBER Docket No. 94N.0012.
Peebles, Ray Stokes, Jr., B. Bochner, Howard J. Zeitz, ed.
Anaphylaxis in the elderly. Immunology and Allergy Clinics of North America. 13 (3): 627-646, August 1993.
Turkeltaub, PC, S. Rastogi. Quantitative intradermal test procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of bioequivalent allergy units to reference preparations using the ID50EAL method, Allergenic Products Testing Laboratory, Center for Biologics Evaluation and Research (CBER), FDA.
Revised November 1994. Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results.
J Allergy Clin Immunol . 1982; 70:343-352. Turkeltaub PC.
Assignment of bioequivalent allergy units based on biological standardization methods. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M . 1988;(82):19-40.
Sheldon, J. M., R. G.
Lovell, K. P. Matthews.
A Manual of Clinical Allergy. Second Edition. W.B.
Saunders, Philadelphia, 1967, pp. 107-112. Sherman, W.
B. Hypersensitivity mechanism and management. W.
B. Sanders, Philadelphia, 1968, pp. 169-172.
Swineford, O. Asthma and Hay Fever. Charles C.
Thomas, Springfield, IL, 1971, pp. 148-155. Patterson, Roy, et al.
Allergy Principles and Practice, 2nd ed. E. Middleton, Jr., C.E.
Reed, E.F. Ellis, Ed., C.V. Mosby Co., 1983, St.
Louis, MO, 1983, Chapter 52. Levy, D.A., L.M. Lichtenstein, E.O.
Goldstein, and K. Ishizaka. Immunologic and cellular changes accompanying the therapy of pollen allergy.
J. Clinical Investigation, 50:360, 1971. Turkeltaub, Paul C., MD, and Peter J.
Gergen, MD. The risk of adverse reactions from percutaneous prick-puncture allergen skin testing, venipuncture, and body measurements: data from the Second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J.
Allergy Clin. Immunol. 84(6): 886-890, Dec.
1989. Pipkorn, Ulf. Pharmacological influence of anti-allergic medication on In Vivo allergen testing.
Allergy. 43: 81-86, 1988. Andersson, M. and U.
Pipkorn. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J.
Allergy Clin. Immunol. 79 (2): 345-349, February 1987.
Rao, Kamineni S., et al. Duration of suppressive effect of tricyclic anti-depressants on histamine induced wheal and flare reactions on human skin. J.
Allergy Clin. Immunol. 82: 752-757, November 1988.
Pipkorn, Ulf, and M. Andersson. Topical dermal anesthesia inhibits the flare but not the wheal response to allergen and histamine in the skin prick test.
Clinical Allergy. 17: 307-311, 1987. Metzger, W.J., E.
Turner and R. Patterson. The safety of immunotherapy during pregnancy.
J. Allergy Clin. Immunol.
61 (4): 268-272, 1978. Reid, M.J., R.F. Lockey, P.C.
Turkletaub, T.A.E. Platts-Mills. Survey of fatalities from skin testing and immunotherapy.
J. Allergy Clin. Immunol.
92 (1): 6-15, July 1993. Reid, M.J., G. Gurka.
Deaths associated with skin testing and immunotherapy. J. Allergy Clin.
Immunol. 97(1) Part 3:231, Abstract 195, January 1996. Thompson, R.A. et al, report of a WHO/IUIS working group.
The current status of allergen immunotherapy (hyposensitization). Allergy. 44: 369-379, 1989.
Malling, H.-J., B. Weeke, et al, The European Academy of Allergology and Clinical Immunology. Position Papers.
Allergy. 48 (Supplement 14): 9-82, 1993. Bernstein IL, Li JT, Bernstein Dl, et al.
Allergy diagnostic testing: an updated… [Excerpted — this section continues on DailyMed.]
📄 Recent Major Changes ▾
RECENT MAJOR CHANGES
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL 5mL Standardized Grass Pollen, Carton 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TS - 5mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TS - 5mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TS - 5mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TS - 5mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TS - 5mL Standardized Grass Pollen, Redtop - Carton Label 0777TS - 5mL Standardized Grass Pollen, Redtop - Container Label 0787TS - 5mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TS - 5mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TS - 5mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TS - 5mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TS - 5mL Standardized Grass Pollen, Timothy - Carton Label 0831TS - 5mL Standardized Grass Pollen, Timothy - Container Label 0841TS - 5mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TS - 5mL Standardized Grass Pollen, Grass Mix 4 - Container Label 10mL Standardized Grass Pollen, Carton 0537TJ - 10mL Standardized Grass Pollen, Bermuda Grass - Carton Label 0537TJ - 10mL Standardized Grass Pollen, Bermuda Grass - Container Label 0545TW - 10mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TW - 10mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TW - 10mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TW - 10mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TW - 10mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TW - 10mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TW - 10mL Standardized Grass Pollen, Redtop - Carton Label 0777TW - 10mL Standardized Grass Pollen, Redtop - Container Label 0787TW - 10mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TW - 10mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TW - 10mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TW - 10mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TW - 10mL Standardized Grass Pollen, Timothy - Carton Label 0831TW - 10mL Standardized Grass Pollen, Timothy - Container Label 0841TW - 10mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TW - 10mL Standardized Grass Pollen, Grass Mix 4 - Container Label 50mL Standardized Grass Pollen, Carton 0537TL - 50mL Standardized Grass Pollen, Bermuda Grass - Carton Label 0537TL - 50mL Standardized Grass Pollen, Bermuda Grass - Container Label 0545TY - 50mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TY - 50mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TY - 50mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TY - 50mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TY - 50mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TY - 50mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TY - 50mL Standardized Grass Pollen, Redtop - Carton Label 0777TY - 50mL Standardized Grass Pollen, Redtop - Container Label 0787TY - 50mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TY - 50mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TY - 50mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TY - 50mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TY - 50mL Standardized Grass Pollen, Timothy - Carton Label 0831TY - 50mL Standardized Grass Pollen, Timothy - Container Label 0841TY - 50mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TY - 50mL Standardized Grass Pollen, Grass Mix 4 - Container Label 5mL Standardized Grass Pollen, Carton 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545… [Excerpted — this section continues on DailyMed.]
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |